Bring antibody discovery in-house with an exclusive antibody discovery platform built specifically for your organization

Specifica builds custom Generation 3 antibody libraries to support internal research and development needs at your lab. Each library combines highly developable therapeutic scaffolds, validated natural diversity, and a unique client-exclusive HCDR3 repertoire to create a discovery platform optimized for affinity, diversity, developability, and speed. Unlike shared libraries, each platform is built exclusively for a single customer, helping maximize epitope coverage while minimizing the risk of overlapping discoveries with competitors.

The Specifica Difference

• • True platform ownership

    Conduct antibody discovery internally while maintaining full control of your programs

  • Exclusivity 

    Client-specific diversity by using a unique donor source

  • No royalties or milestone fees

    Straightforward business terms designed to support long-term innovation

  • Proven results

  • Nine of the top 20 pharma companies have a custom Specifica antibody library. With 30 custom libraries and counting, our platform supports discovery at large companies, emerging biopharma, academic and AI companies.

Our approach virtually eliminates the risk of pursuing an antibody already identified by a competitor.  The importance of this became clear when Genentech and Human Genome Sciences independently discovered identical antibodies against the same target from the same phage display library, leading to a patent dispute. The rise of next-generation sequencing has only heightened this risk.

Available formats include VHH, scFv and Fab. Our scFv and Fab libraries are also available with common light chains. We can build libraries across all formats or just a single sub-library.

Specifica doesn’t charge royalties, milestone-based fees or “research” fees for our work. We value transparency and clarity in our scientific and business and practices. You’ll know costs upfront before we start, and we won’t ask you to share your intellectual property or pay us licensing fees in perpetuity. Your molecules are yours; we won’t ask you to report back to us or allow us to conduct any audits.

The quality of our libraries and processes reduces your need for additional downstream affinity or developability improvement. This is true whether we perform a discovery campaign, optimization project or build you an exclusive library.